GeneDx is attending the Rare Trials Summit for a discussion on how genetically confirmed patient cohorts and real-world clinical data can help accelerate rare disease research and trial planning alongside leaders from UCB and Neurvati Neurosciences.
Published
Signal category
Presence & Recognition
Quote
“Join GeneDx's Colleen Caleshu MSc, LCGC, PhD Candidate , alongside leaders from UCB and Neurvati Neurosciences, at the Rare Trials Summit for a discussion on how genetically confirmed patient cohorts and real-world clinical data can help accelerate rare disease research and trial planning.”
— GeneDx team
Company
GeneDx
Empowering everyone to live their healthiest life through genomics
- Industry
- Biotechnology Research
- Location
- Stamford, US
- Company size
- 1,293 employees
We see a world where every genetic condition is understood, and every patient receives the care they need to live their healthiest life through genomics. GeneDx combines unmatched clinical expertise, advanced technology, and the power of GeneDx Infinity™, the world’s largest rare disease genomic dataset. This unparalleled foundation powers GeneDx’s ExomeDx™ and GenomeDx™ tests – ranked #1 by expert geneticists and granted FDA Breakthrough Device Designation – enabling clinicians to deliver precise, fast, and actionable diagnoses. With over 25 years of innovation, more than 4,800 genetic diseases diagnosed, and over 1,000 scientific publications, we’re building the genomic intelligence network that’s shaping the future of precision medicine: for patients, providers, and partners alike.